|
COMMERCE BUSINESS DAILY ISSUE OF MAY 12,1999 PSA#2344National Cancer Institute, Research Contracts Branch, PSAS, 6120
Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227 B -- ANALYSIS OF NCI OUTREACH COMMUNICATION STRATEGY SOL
NCI-RFQ090098-NV DUE 052499 POC Debbie Moore, Purchasing Agent,
301-402-4509, Todd Cole, Contracting Officer, 301-402-4509 RFQ-NCI
90098-NV for "Analysis of NCI Outreach Communication Strategy," which
was issued as a combined synopsis/solicitation in the Commerce Business
Daily (CBDNet) on April 28, 1999, is amended to provide answers to
questions raised by prospective offerors. Additionally, a deadline for
any additional questions has been set for May 17, 1999 at 11:00 AM
EST. After the foregoing deadline has passed, there is no guarantee
that a timely response will be forthcoming prior to the due date of
offers which is now changed to May 24, 1999 at 3:00 PM EST. The
following questions were submitted to the NCI Purchasing Agent and
answers immediately follow as designated: Question 1. What is the NCI
organizational structure? How many divisions, departments, and
departments make up the National Cancer Institute? ANSWER 1: The
organizational structure, along with all organizational entities
(divisions, branches, etc.), are available at
http://www.nci.nih.gov/mab/orgchart.htm . The National Cancer Institute
employs approximately 2,800 people. Question 2: Is all staff located at
the Executive Boulevard address? If not, where are additional
locations? Answer 2: Not all staff are located at the Executive
Boulevard address. There are staff throughout the locales encompassing
Frederick, MD (approximately 400 employees) and Bethesda, MD
(approximately 2,400 employees). Question 3: Does NCI currently have a
fully integrated, internal communications system of any kind? If so,
what system is currently in place? Answer 3: Internal messages and
communications are accomplished via e-mail and voice mail. In addition,
communication is also accomplished through NIH interoffice mail.
Question 4: How many products does NCI currently have? Answer 4: NCI is
not oriented organizationally to being a product provider; however,
cancer-related information is widely disseminated by NCI. It is for
this reason that the analysis is necessary. The answer to this question
shall be determined by the required analysis that is to be performed
under this requirement. Within the CBD synopsis/solicitation, "C.
Information Reporting" provides additional detail. Question 5: In
reference to Background Information and Analyses, will the noted
information be gathered by NCI personnel and provided to the
consultant? Answer 5: Yes, NCI will provide the information to the
Contractor after the anticipated award. NCI does not have the
information consolidated at this time; however, collection and
consolidation is not part of the requirement. Question 6: Will the
Audience Analysis be gathered by NCI personnel and provided to the
contractor? Answer 6: Yes, NCI will provide the audience analysis to
the Contractor. Based on the information, the Contractor is required to
"develop one or more models of the types of information that NCI should
provide and what the NCI product lines might look like" (See C.
Paradigm Development). Question 7: Who and at what rate will the Panel
of Expert members be compensated? How many participation hours does
the NCI recommend/anticipate for thePanel of Expert members per week or
during the 6-month period? Does the NCI anticipate this team to be a
standing committee (long-term)? The Contractor is required to recommend
a panel of experts to NCI. If necessary, the National Cancer Institute
will compensate any panel members without Contractor involvement. The
number of meeting and subsequent hours of panel participation is not
known at this time without the initial analyses that the Contractor is
to perform. However, the number of hours to be performed by the
Contractor (500 hours) encompasses the meeting time with the panel and
all other activities to be performed. NCI does not anticipate a
standing committee that will continue long-term. Previous CBD Cite:
(W-118 SN325382) Posted 05/10/99 (W-SN329504). (0130) Loren Data Corp. http://www.ld.com (SYN# 0011 19990512\B-0002.SOL)
B - Special Studies and Analyses - Not R&D Index Page
|
|